Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease.

British journal of haematology - 1 Dec 2024

Liu Weiyang, Wang Cheng, Ouyang Wanyan, Hao Jie, Ren Jiayi, Peng Lijun, Tang Sijie, Liu Yuanfang, Zhu Yongmei, Weng Xiangqin, Jing Duohui, Chen Saijuan, Wang Jin, Mi Jian-Qing

Abstract excerpt

Third-generation tyrosine kinase inhibitors (TKIs) have much potential for the treatment of BCR::ABL1-positive leukaemia, particularly that harbouring the ABL1 T315I mutation. Olverembatinib (HQP1351), a novel third-generation TKI, has favourable efficacy and safety profiles in chronic myeloid leukaemia. Here, we present the clinical findings from 31 BCR::ABL1-positive acute lymphoblastic leukaemia (ALL) patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematopoietic Stem Cell Transplantation

Share to Neoplasm, Residual

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Protein Kinase Inhibitors

Share to Recurrence

Share to Treatment Outcome

Source

Identifiers

PMID: 39363594
DOI: 10.1111/bjh.19804

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease.PMID 39363594Read ↗

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Semantic proximity Read ↗

Olverembatinib combined with inotuzumab ozogamicin in relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report.Semantic proximity Read ↗

Olverembatinib (HQP1351), a highly safe and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialSemantic proximity Read ↗

Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report.Semantic proximity Read ↗

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.Semantic proximity Read ↗

Olverembatinib: First Approval.Semantic proximity Read ↗

New ABL1 Kinase Domain Mutations in BCR::ABL1-Positive Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive LeukemiasSemantic proximity Read ↗

T315I-mutated chronic myeloid leukemia with blast crisis relapse 10 years after allo-HSCT: A case report of second transplantation combined with olverembatinib maintenance therapy.Semantic proximity Read ↗

Efficacy and Safety of the Third‐Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination With Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia Patients With Refractory/Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell TransplantationSemantic proximity Read ↗

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE TrialSemantic proximity Read ↗

Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.